Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.
So today I am presenting the results of the Margo trial. This was a trial that was looking at maritima versus trastuzumab for patients with early stage, her two positive breast cancer maritima is an anti, her two antibody just like trastuzumab. But it was specifically engineered to try to optimize the immune characteristics and the immune efficacy of the antibody therapy. And in the metastatic setting from the randomized three Sophia trial, we know that maritima combined with chemotherapy is modestly better than the older antibody trastuzumab combined with chemotherapy for patients with pretreated and refractory her two positive metastatic breast cancer. So our, our goal in the Margot trial was to understand whether that modest improvement in efficacy with Margit a seen in the metastatic setting would translate into the early stage setting. So we conducted this randomized uh trial again. Um with stage two and three, her two positive breast cancer patients, patients were randomized to either the T MP regimen which was 12 weeks of paclitaxel with Margita Maab and Pertuzumab or the THP regimen, which was 12 weeks of paclitaxel with trastuzumab uh and Pertuzumab. So it was ATM P versus THP comparison. The primary endpoint was pathologic complete response or PC R. Uh with respect to the primary end point, we found that there was no statistically significant difference between the two regimens with respect to PC R. So the PC R rate for THP was 46%. The PC R rate for T MP was 56%. Those were not statistically different um in the design of the trial. So obviously, there was a numerical difference with a 10% improvement in PC R rate um for the T MP regimen. But that was not statistically significant.
